Showing posts from January, 2024Show all
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) health-issue

Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)

Nitesh sinha January 25, 2024

https://ift.tt/Aqzhbya from Sanofi - Aventis Groupe https://ift.tt/PQMzayZ via IFTTT

Read more
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline health-issue

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

Nitesh sinha January 22, 2024

https://ift.tt/Kl9DIjw   from Sanofi - Aventis Groupe https://ift.tt/ZbBke74 via IFTTT

Read more
Media Update: Dupixent® (dupilumab) U.S. label updated with data further supporting use in atopic dermatitis with moderate-to-severe hand and foot involvement health-issue

Media Update: Dupixent® (dupilumab) U.S. label updated with data further supporting use in atopic dermatitis with moderate-to-severe hand and foot involvement

Nitesh sinha January 16, 2024

https://ift.tt/s0lOVQM from Sanofi - Aventis Groupe https://ift.tt/CLPUQ4n via IFTTT

Read more
Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee health-issue

Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee

Nitesh sinha January 09, 2024

https://ift.tt/jkugvqX   from Sanofi - Aventis Groupe https://ift.tt/W3z9Rxg via IFTTT

Read more